Eli Lilly Cuts Zepbound Price to Widen Access for Obesity Drug

The Eli Lilly logo on one of the company’s offices in San Diego, Calif., on Sept. 17, 2020. Mike Blake/ReutersEli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies surge.Patients with a prescription can now buy the starting dose of 2.5 mg for $299 per month, down from $349, through LillyDirect, the drugmaker’s online healthcare platform.